Jamie A. Donadio


Jamie A. Donadio joined BioTheryX, Inc. as its Chief Financial Officer in February 2021. Mr. Donadio holds over 20 years of finance and accounting experience, including 19 years at publicly held biopharmaceutical companies from development stage through commercialization. Prior to BioTheryX, Mr. Donadio served as Chief Financial Officer at Mirati Therapeutics, Inc. a publicly traded, targeted oncology company where he helped the Company raise over $800 million through public equity offerings. At Mirati, Mr. Donadio also played a key role in the Company’s reorganization and relocation to San Diego, as well as its Nasdaq listing and subsequent growth. Prior to Mirati, Mr. Donadio held roles of increasing responsibility at Amylin Pharmaceuticals, Inc. most recently serving as Senior Director of Finance where he played an important role in the Company’s acquisition by Bristol Myers Squibb, Inc.. Prior to Amylin, Mr. Donadio held roles at Novatel Wireless, Inc. and Ernst & Young LLP. Mr. Donadio holds a B.S. in Accounting from Babson College and is a certified public accountant (inactive) in the State of California.